Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.97 USD | +6.93% |
|
+9.01% | +15.62% |
Jun. 25 | Oppenheimer Initiates Keros Therapeutics at Outperform With $102 Price Target | MT |
Jun. 18 | Keros Therapeutics Names Chief Executive Officer Jasbir Seehra as Board Chair | MT |
Evolution of the average Target Price on Keros Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
![Consensus](/images/consensus_flch.gif)
Consensus detail
Consensus revision (last 18 months)
Analysts covering Keros Therapeutics, Inc.
Wedbush | |
BofA Securities | |
Piper Sandler | |
Cowen | |
BTIG | |
Truist Securities |
EPS Revisions
- Stock Market
- Equities
- KROS Stock
- Consensus Keros Therapeutics, Inc.